Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N05AH02 CLOZAPINUM COMPR. 100 mg

LEPONEX(R) 100 mg 100 mg NOVARTIS PHARMA GMBH
N05AH02 CLOZAPINUM COMPR. 25 mg

LEPONEX(R) 25 mg 25 mg NOVARTIS PHARMA GMBH

________________________________________________________________________________
SUBLISTA C1 - G13 MIASTENIA GRAVIS.
______________________________________________________________________________

| 472 |H02AB07| PREDNISONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB07 PREDNISONUM COMPR. 5 mg

N - PREDNISON 5 mg MEDUMAN SA

PREDNISON 5 mg 5 mg SINTOFARM SA

PREDNISON ARENA 5 mg 5 mg ARENA GROUP SA

PREDNISON GEDEON RICHTER 5 mg 5 mg GEDEON RICHTER ROMANIA SA

PREDNISON MAGISTRA 5 mg 5 mg MAGISTRA C & C

________________________________________________________________________________

______________________________________________________________________________

| 473 |L01BA01| METHOTREXATUM (4) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01BA01 METHOTREXATUM

________________________________________________________________________________
______________________________________________________________________________

| 474 |L04AX01| AZATHIOPRINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
______________________________________________________________________________

| 475 |N07AA01| NEOSTIGMINI BROMIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N07AA01 NEOSTIGMINI BROMIDUM SOL. INJ. 0.5 mg/ml

MIOSTIN 0,5 mg/ml 0.5 mg/ml ZENTIVA S.A.
N07AA01 NEOSTIGMINI BROMIDUM COMPR. 15 mg

NEOSTIGMINA LPH 15 mg 15 mg LABORMED PHARMA SA

________________________________________________________________________________
______________________________________________________________________________

| 476 |N07AA02| PYRIDOSTIGMINI BROMIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

N07AA02 PYRIDOSTIGMINI DRAJ. 60 mg

BROMIDUM

MESTINON 60 mg 60 mg ICN POLFA RZESZOW S.A.

________________________________________________________________________________
SUBLISTA C1 - G14 SCLEROZA MULTIPLĂ.
______________________________________________________________________________

| 477 |H02AB04| METHYLPREDNISOLONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 125 mg

LEMOD SOLU 125 mg 125 mg HEMOFARM S.R.L.
H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. 125 mg/2 ml

SOL. INJ.

SOLU - MEDROL ACT-O-VIAL 125 mg/2 ml PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 16 mg

MEDROL A 16 16 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 20 mg

LEMOD SOLU 20 mg 20 mg HEMOFARM S.R.L.

H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. 250 mg/4 ml

SOL. INJ.

SOLU - MEDROL ACT-O-VIAL 250 mg/4 ml PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 32 mg

MEDROL 32 32 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 40 mg

LEMOD SOLU 40 mg 40 mg HEMOFARM S.R.L.

H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. 40 mg/1 ml

SOL. INJ.

SOLU - MEDROL ACT-O-VIAL 40 mg/1 ml PFIZER EUROPE MA EEIG
H02AB04 METHYLPREDNISOLONUM COMPR. 4 mg

MEDROL 4 mg 4 mg PFIZER EUROPE MA EEIG

H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ. 500 mg

LEMOD SOLU 500 mg 500 mg HEMOFARM S.R.L.

H02AB04 METHYLPREDNISOLONUM LIOF. + SOLV. PT. SOL. 500 mg/7.8 ml

INJ.

SOLU - MEDROL 500 mg/7,8 ml 500 mg/7.8 ml PFIZER EUROPE MA EEIG

________________________________________________________________________________

______________________________________________________________________________

| 478 |H02AB07| PREDNISONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB07 PREDNISONUM COMPR. 5 mg

N - PREDNISON 5 mg MEDUMAN SA

PREDNISON 5 mg 5 mg SINTOFARM SA

PREDNISON ARENA 5 mg 5 mg ARENA GROUP SA

PREDNISON GEDEON RICHTER 5 mg 5 mg GEDEON RICHTER ROMANIA SA

PREDNISON MAGISTRA 5 mg 5 mg MAGISTRA C & C

________________________________________________________________________________

______________________________________________________________________________

| 480 |L01DB07| MITOXANTRONUM*** | Protocol: L001G |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01DB07 MITOXANTRONUM CONC. PT. SOL. PERF. 2 mg/ml

MITOXANTRONE TEVA 2 mg/ml 2 mg/ml TEVA PHARMACEUTICALS SRL
L01DB07 MITOXANTRONUM SOL. PERF. 20 mg/10 ml

NOVANTRONE 20 mg/10 ml WYETH LEDERLE PHARMA GMBH

L01DB07 MITOXANTRONUM CONC. PT. SOL. INJ. 2 mg/ml

ONKOTRONE 2 mg/ml BAXTER ONCOLOGY GMBH

________________________________________________________________________________
______________________________________________________________________________

| 481 |L04AX01| AZATHIOPRINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
SUBLISTA C1 - G15 BOLI PSIHICE (SCHIZOFRENIE, TULBURĂRI SCHIZOTIPALE ŞI DELIRANTE, TULBURĂRI AFECTIVE MAJORE, TULBURĂRI PSIHOTICE ACUTE ŞI BOLI PSIHICE COPII, AUTISM).
______________________________________________________________________________

| 482 |N03AG01| ACIDUM VALPROICUM + SĂRURI | |

|_______|_______|____________________________________________|_________________|
S-au raportat cazuri de hepatotoxicitate letală, în special la copii. Se înregistrează din ce în ce mai multe dovezi cu privire la teratogenitatea legată de doză.